Effects of Dietary Calcium Supplementation on Bone Metabolism, Kidney Mineral Concentrations, and Kidney Function in Rats Fed a High-Phosphorus Diet

Katsumata, Seishi; Matsuzaki, Hiroshi; Uehara, Mariko; Suzuki, Kazuharu

doi:10.3177/jnsv.61.195

Cited by 11 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Femur RANKL mRNA was increased with high dietary phosphorus in both younger and older mice, but the RANKL:OPG mRNA ratio was only increased in the old mice, suggesting that the effects of high dietary phosphorus on bone resorption are more pronounced with aging. In a second study, Katsumata et al (55) further investigated the effects and interaction between high dietary calcium and phosphorus on bone outcomes in rats. Rats were fed either adequate calcium (0.5%) or high calcium (1.0%) and either adequate phosphorus (0.3%) or high phosphorus (1.5%) in a 2×2 factorial design.…”

Section: High Dietary Phosphorus Intake Effects On Bone Healthmentioning

confidence: 99%

Effects of Excessive Dietary Phosphorus Intake on Bone Health

Vorland

Stremke

Moorthi

et al. 2017

Curr Osteoporos Rep

View full text Add to dashboard Cite

Purpose of Review The purpose of this review is to provide an overview of dietary phosphorus, its sources, recommended intakes, and its absorption and metabolism in health and in chronic kidney disease, and to discuss recent findings in this area with a focus on the effects of inorganic phosphate additives in bone health. Recent Findings Recent findings show that increasing dietary phosphorus through inorganic phosphate additives has detrimental effects on bone and mineral metabolism in humans and animals. There is new data supporting an educational intervention to limit phosphate additives in patients with chronic kidney disease to control serum phosphate. Summary The average intake of phosphorus in the US well-above the recommended dietary allowance. Inorganic phosphate additives, which are absorbed at a high rate, account for a substantial and likely underestimated portion of this excessive intake. These additives have negative effects on bone metabolism, and present a prime opportunity to lower total phosphorus intake in the U.S. Further evidence is needed to confirm whether lowering dietary phosphorus intake would have beneficial effects to improve fracture risk.

show abstract

Section: High Dietary Phosphorus Intake Effects On Bone Healthmentioning

confidence: 99%

Effects of Excessive Dietary Phosphorus Intake on Bone Health

Vorland

Stremke

Moorthi

et al. 2017

Curr Osteoporos Rep

View full text Add to dashboard Cite

show abstract

“…However, HCD supplementation significantly increased SCa, bone Ca content and Ca/Ash, whilst bone loss of lumbar vertebrae in 5/6 Nx mice was ameliorated. A previous study indicated that dietary Ca supplementation inhibits RANKL-mediated osteoclastic bone resorption via the suppression of PTH (8). Thus, these findings suggest that HCD supplementation may increase bone Ca content and bone remodeling via inhibiting RANKL-induced bone resorption in 5/6 Nx mice.…”

Section: Discussionmentioning

confidence: 72%

“…Epidemiological studies have demonstrated that Ca supplementation has beneficial effects on bone mineral content and bone mineral density (BMD) (6,7). In rats, Ca supplementation prevented the bone loss and decline in kidney function induced by a high-P diet (8). Furthermore, a high calcium diet (HCD) increases bone mineral (Ca and P) content in high-fat diet-induced obese mice (9).…”

Section: Introductionmentioning

confidence: 99%

High calcium diet alleviates 5/6 nephrectomy-induced bone deteriorations of lumbar vertebrae in mice

et al. 2018

View full text Add to dashboard Cite

Abstract. Dietary calcium (Ca) supplementation has beneficial effects on bone health. However, it is not clear whether a high calcium diet (HCD) following 5/6 nephrectomy (5/6 Nx) is beneficial to bone health. The aim of the present study was to examine the effects of an HCD on bone metabolism using a chronic kidney disease (CKD) mouse model. Male C57BL/6J mice were divided into three groups: Sham group, 5/6 Nx group and 5/6 Nx + HCD group. Mice were sacrificed 12 weeks post-surgery. Calcium (Ca) and creatinine (Cr) were measured using standard colorimetric methods and picric acid methods, respectively. Bone metabolism-associated markers, FGF-23, PTH, ALP-b and TRAP-5b were measured using ELISA kits. Lumbar vertebrae histomorphological analysis was performed using hematoxylin and eosin staining. The expression of osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL) mRNA was detected using reverse transcription-quantitative polymerase chain reaction. Impaired renal function and histopathological damage was indicated in 5/6 Nx mice. However, HCD had no significant effects on these changes in 5/6 Nx mice. Notably, mineral metabolism disorder and histopathological damage to lumbar vertebrae were markedly improved in HCD-treated 5/6 Nx mice. Compared with 5/6 Nx mice, HCD supplementation significantly elevated the ratio of OPG/RANKL and inhibited RANKL mRNA expression in lumbar vertebrae. To conclude, the present findings indicated that increased Ca intake is effective in increasing bone mineral content of the lumbar vertebrae in 5/6 Nx mice. These results may provide a basis for the clinical use of dietary Ca supplementation as a therapeutic approach to treat CKD-induced disturbance of mineral metabolism and bone loss.

show abstract

“…These pharmacologic therapies can also alter the phosphorus/calcium ratio. The reduction of phosphorus can alter the calcium absorption, while increased phosphorus concentrations can increase the oxidative stress as well as the hormonal balance between phosphates, calcium, and vitamin D. This might be conducive to adverse effects on mineral metabolism and increased bone loss [49,50].…”

Section: Discussionmentioning

confidence: 99%

“…Alkaline phosphatase and osteocalcin are both bone formation markers [50,51]. Bone alkaline phosphatase (ALP) regulates bone mineralization [51].…”

Section: Discussionmentioning

confidence: 99%

Systematic Review of the Long-Term Effects of Transgender Hormone Therapy on Bone Markers and Bone Mineral Density and Their Potential Effects in Implant Therapy

Delgado-Ruíz

Swanson

Romanos

2019

JCM

View full text Add to dashboard Cite

This study seeks to evaluate the long-term effects of pharmacologic therapy on the bone markers and bone mineral density of transgender patients and to provide a basis for understanding its potential implications on therapies involving implant procedures. Following the referred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and well-defined PICOT (Problem/Patient/Population, Intervention, Comparison, Outcome, Time) questionnaires, a literature search was completed for articles in English language, with more than a 3 year follow-up reporting the long-term effects of the cross-sex pharmacotherapy on the bones of adult transgender patients. Transgender demographics, time under treatment, and treatment received were recorded. In addition, bone marker levels (calcium, phosphate, alkaline phosphatase, and osteocalcin), bone mineral density (BMD), and bone turnover markers (Serum Procollagen type I N-Terminal pro-peptide (PINP), and Serum Collagen type I crosslinked C-telopeptide (CTX)) before and after the treatment were also recorded. The considerable variability between studies did not allow a meta-analysis. All the studies were completed in European countries. Transwomen (921 men to female) were more frequent than transmen (719 female to male). Transwomen’s treatments were based in antiandrogens, estrogens, new drugs, and sex reassignment surgery, meanwhile transmen’s surgeries were based in the administration of several forms of testosterone and sex reassignment. Calcium, phosphate, alkaline phosphatase, and osteocalcin levels remained stable. PINP increased in transwomen and transmen meanwhile, CTX showed contradictory values in transwomen and transmen. Finally, reduced BMD was observed in transwomen patients receiving long-term cross-sex pharmacotherapy. Considering the limitations of this systematic review, it was concluded that long-term cross-sex pharmacotherapy for transwomen and transmen transgender patients does not alter the calcium, phosphate, alkaline phosphatase, and osteocalcin levels, and will slightly increase the bone formation in both transwomen and transmen patients. Furthermore, long-term pharmacotherapy reduces the BMD in transwomen patients.

show abstract

Effects of Dietary Calcium Supplementation on Bone Metabolism, Kidney Mineral Concentrations, and Kidney Function in Rats Fed a High-Phosphorus Diet

Cited by 11 publications

References 22 publications

Effects of Excessive Dietary Phosphorus Intake on Bone Health

Effects of Excessive Dietary Phosphorus Intake on Bone Health

High calcium diet alleviates 5/6 nephrectomy-induced bone deteriorations of lumbar vertebrae in mice

Systematic Review of the Long-Term Effects of Transgender Hormone Therapy on Bone Markers and Bone Mineral Density and Their Potential Effects in Implant Therapy

Contact Info

Product

Resources

About